2 completed, 1 not yet recruiting, 1 terminated. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Not yet recruiting 1, Terminated 1 |
Follow Se-Hoon Lee: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC Tislelizumab, Fecal Microbiota Transplant(FMT) - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Se-Hoon Lee | 15 | 2026-09-30 | 2026-08-11 |
| Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects Olaparib+Bevacizumab to SCLC patients - Lung Cancer | Phase 2 | Completed | Se-Hoon Lee | 25 | 2021-06-11 | 2024-01-02 |
| AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer Durvalumab+AZD2811 to SCLC patients - SCLC, Recurrent | Phase 2 | Terminated | Se-Hoon Lee | 4 | 2020-09-18 | 2022-02-25 |
| Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects Durvalumab - Small Cell Lung Cancer | Phase 2 | Completed | Se-Hoon Lee | 42 | 2020-06-17 | 2024-01-03 |
Small Cell Lung Carcinoma (2) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Recurrence (1)
Fecal Microbiota Transplantation (1) · ceralasertib (1) · durvalumab (1) · tislelizumab (1)
South Korea (3)